Early Alzheimer’s Guidance: FDA Puts Forth New Endpoint Possibilities for Stage 3 Disease

 
• By Sarah Karlin-Smith
  
PET scan images of the human brain
New endpoint flexibility in FDA guidance could make for shorter clinical trials in Stage 3 Alzheimer's disease • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership